Nephrology Forum

Kidney International (1980) 17, 677–693; doi:10.1038/ki.1980.79

Renal osteodystrophy

Presentation of this Forum is made possible by grants from Hoechst-Roussel Pharmaceuticals Inc., Smith Kline & French Laboratories, G. D. Searle & Co., Warner-Lambert Pharmaceutical Division, Burroughs Wellcome Company, Geigy Pharmaceuticals Inc., Ciba Pharmaceuticals Inc., and Boehringer Ingel-heim Ltd.

Principal Discussant: Jack W Coburn1

1Nephrology Section, VA Wadsworth Medical Center and UCLA School of Medicine, Los Angeles, California

Correspondence: Dr Jack W Coburn, Nephrology Section, VA Wadsworth Medical Center, Wilshire and Sawtelle Boulevards, Los Angeles, California 90073.

Top

References

  1. Coburn JW, Llach F, Kurokawa K: Altered divalent ion metabolism in renal disease and renal osteodystrophy, in Clinical Disorders of Fluid and Electrolyte Metabolism, edited by Maxwell MH, Kleeman CR, New York, McGraw-Hill Publishing Co, 1980, p. 1153
  2. Slatopolsky E, Caglar S, Pennell JP, Taggart DD, Canterbury JM, Reiss E, Bricker NS: On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J Clin Invest 50:492–499, 1971 | PubMed | ISI | ChemPort |
  3. Slatopolsky E, Caglar S, Gradowska L, Canterbury JM, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 2:147–151, 1972 | PubMed | ISI | ChemPort |
  4. Slatopolsky E, Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4:141–145, 1973 | PubMed | ISI | ChemPort |
  5. Rutherford WE, Bordier P, Marie P, Hruska K, Harter H, Greenwalt A, Blondin J, Haddad J, Bricker NS, Slatopolsky E: Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest 60:332–341, 1977
  6. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW: Skeletal resistance of endogenous parathyroid hormone in patients with early renal failure: A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 41:338–345, 1975
  7. Coburn JW, Koppel MH, Brickman AS, Massry SG: Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3:264–272, 1973 | PubMed | ISI | ChemPort |
  8. Coburn JW, Popovtzer MM, Massry SG, Kleeman CR: The physiochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med 124:302–311, 1969 | Article | PubMed | ChemPort |
  9. Coburn JW, Hartenbower DL, Brickman AS: Advances in vitamin D metabolism as they pertain to chronic renal disease. Am J Clin Nutr 29:1283–1299, 1976
  10. Ponchon G, DeLuca HF: The role of the liver in the metabolism of vitamin D. J Clin Invest 48:1273–1279, 1969 | PubMed | ChemPort |
  11. Smith JE, Goodman DS: The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest 50:2159–2167, 1971
  12. Fraser DR, Kodicek E: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228:764–766, 1970 | Article | PubMed | ChemPort |
  13. Myrtle JF, Norman AW: Vitamin D: A cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science 171:79–82, 1971 | PubMed | ChemPort |
  14. Boyle IT, Gray RW, DeLuca HF: Regulation by calcium of in vivo synthesis of 1,25-dihydroxycholecalciferol and 21,25-dihydroxycholecalciferol. Proc Natl Acad Sci USA 68:2131–2134, 1971
  15. Henry HL, Midgett RJ, Norman AW: Regulation of 25-hydroxyvitamin D3-l-hydroxylase in vivo. J Biol Chem 249:7584–7592, 1974 | PubMed | ChemPort |
  16. Booth BE, Tsai HC, Morris RC: Parathyroidectomy reduces 25-hydroxy-vitamin D3-1alpha-hydroxylase activity in the hypocalcalcemic vitamin D-deficient chick. J Clin Invest 60:1314–1320, 1977
  17. Tanaka Y, DeLuca HF: The control of 25-hydroxy-vitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 154:566–574, 1973 | Article | PubMed | ISI | ChemPort |
  18. Larkins RG, MacAuley SJ, Rapoport A, Martin TJ, Tulloch BR, Byfield PGH, Matthews EW, Macintyre I: Effects of nucleotides, hormones, ions, and 1,25-dihydroxycholecalciferol on 1,25-d-hydroxycholecalciferol production in isolated chick renal tubules. Clin Sci Mol Med 46:559–582, 1974a
  19. Malluche HH, Werner E, Ritz E: Intestinal absorption of calcium and whole body calcium retention in incipient and advanced renal failure. Min Electrol Metab 1:263–270, 1978
  20. Slatopolsky E, Gray R, Adams ND, Lewis J, Hruska K, Martin K, Klahr E, DeLuca HF, Lemann J: Low serum levels of 1,25(OH)2D3 are not responsible for the development of secondary hyperparathyroidism in early renal failure. Kidney Int 14:733, 1978
  21. Portale AA, Boorth BE, Tsai HC, Morris RC: Reduced plasma concentration of 1,25(OH)2D in children with moderate renal insufficiency. Kidney Int 16:922, 1979 (abstract)
  22. Llach F, Massry SG, Koffler A, Malluche HH, Singer FR, Brickman AS, Kurokawa K: Secondary hyperparathyroidism in early renal failure: Role of phosphate retention. Kidney Int 12:459, 1977
  23. Brumbaugh PF, Haussler DH, Bressler R, FIaussler MR: Radio-receptor assay for lalpha,25-dihydroxy-vitamin D3. Science 183:1089–1091, 1974 | PubMed | ChemPort |
  24. Eisman JA, Hamstra AJ, Kream BE, DeLuca HF: 1,25-dihydroxy-vitamin D in biological fluids: A simplified and sensitive assay. Science 193:1021–1023, 1976
  25. Brickman AS, Coburn JW, Norman AW: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. N Engl J Med 287:891–895, 1972 | PubMed | ISI | ChemPort |
  26. Brickman AS, Coburn JW, Massry SG, AW: 1,25-dihydroxy-vitamin D3 in normal man and patients with renal failure. Ann Intern Med 80:161–168, 1974 | PubMed | ISI | ChemPort |
  27. Henderson RG, Russell RGG, Ledingham JGG, Smith R, Oliver DO, Walton RJ, Small DG, Preston C, Warner GT, Norman AW: Effects of 1,25-dihydroxy-cholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 1:379–384, 1974
  28. Brickman AS, Sherrard DJ, Jowsey J, Singer FR, Baylink DJ, Maloney N, Massry SG, Norman AW, Coburn JW: 1,25-dihydroxycholecalciferol: Effect on skeletal lesions and plasma parathyroid hormone in uremic osteodystrophy. Arch Intern Med 134:883–888, 1974
  29. Chesney RW, Moorthy AV, Eisman JA, Jax DK, Mazess RB, DeLuca HF: Increased growth after long-term and lalpha,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 298:238–242, 1978 | PubMed |
  30. Brumbaugh PF, Hughes MR, Haussler MR: Cytoplasmic and nuclear binding components for 1-alpha,25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci USA 72:4871–4875, 1975
  31. Chertow BS, Baylink DJ, Wergedal JF, Su MHH, Norman AW: Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest 56:668–678, 1975
  32. Tanaka Y, DeLuca HF, Ghazarian JG, Hargis GK, Williams GA: The effect of vitamin D and its metabolites on serum parathyroid hormone levels in the rat. Min Electrol Metab 2:20–25, 1979
  33. Llach F, Coburn JW, Brickman AS, Kurokawa K, Norman AW, Canterbury JM, Reiss E: Acute actions of 1,25-dihydroxy-vitamin D3 in normal man: Effect on calcium and parathyroid status. J Clin Endocrinol Metab 44:1054–1060, 1977
  34. Oldham SB, Smith R, Hartenbower DL, Henry HL, Norman AW, Coburn JW: The acute effects of 1,25-dihydroxycholecalciferol on serum immunoreactive parathyroid hormone (iPTH) in the dog. Endocrinology 104:248–254, 1979
  35. Recker RR, Saville PD: Calcium absorption in renal failure: Its relationship to blood urea nitrogen, dietary calcium intake, time on dialysis, and other variables. J Lab Clin Med 78:380–388, 1971
  36. Duursma SA, Visser WJ, Nijo L: A quantitative histological study of bone in 30 patients with renal insufficiency. Calcif Tissue Res 9:216–225, 1972
  37. Sherrard DJ, Baylink DJ, Wergedal JE, Maloney N: Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab 39:119–135, 1974 | PubMed | ISI | ChemPort |
  38. Bordier PJ, Tun-Chot S, Eastwood JB, Fournier A, De Wardener HE: Lack of histological evidence of vitamin D abnormality in the bones of anephric patients. Clin Sci 44:33–41, 1973 | PubMed | ChemPort |
  39. Kanis JA, Adams ND, Earnshaw M, Heynen G, Ledingham JGG, Oliver DO, Russell RGG, Woods CG: Vitamin D, osteomalacia and chronic renal failure, in Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism, edited by Norman AW, Schaefer K, Coburn JW, DeLuca HF, Fraser D, Grigoleit HG, von Herrath D, Berlin, W De Gruyter, 1977, p. 671
  40. Massry SG, Coburn JW, Lee DBN, Jowsey J, Kleeman CR: Skeletal resistance to parathyroid hormone in renal failure: Study in 105 human subjects. Ann Intern Med 78:357–364, 1973 | PubMed | ISI | ChemPort |
  41. Massry SG, Stein R, Garty J, Arieff AI, Coburn JW, Norman AW, Friedler RM: Skeletal resistance to the calcemic action of parathyroid hormone in uremia: Role of 1,25(OH)2D3. Kidney Int 9:467–474, 1976 | PubMed | ISI | ChemPort |
  42. Sommervile PJ, Kaye M: Resistance to parathyroid hormone in renal failure: Role of vitamin D metabolites. Kidney Int 14:245–254, 1978
  43. Hahn TJ, Avioli LV: Anticonvulsant osteomalacia. Arch Intern Med 135:997–1000, 1975
  44. Hahn TJ: Bone complications of anticonvulsants. Drugs 12:201–211, 1976
  45. Jubiz W, Haussler MR, McCain TA, Tolman KO: Plasma 1,25-dihydroxy-vitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 44:617–621, 1977 | PubMed | ChemPort |
  46. Hahn TJ, Birge SJ, Scharp CR, Avioli LV: Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest 51:741–748, 1972
  47. Pierides AM, Kerr DN, Ellis HA, ORiordan JLH, DeLuca HF: 1alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy. Clin Nephrol 5:189–196, 1976
  48. Pierides AM, Ellis HA, Ward M, Simpson W, Peart KM, Alvarez-Ude F, Uldall PR, Kerr DNS: Barbiturate and anticonvulsant treatment in relation to osteomalacia with haemodialysis and renal transplantion. Br Med J 1:190–193, 1976
  49. Massry SG, Goldstein DA: Role of parathyroid hormone in uremic toxicity. Kidney Int 13:S39–S42, 1978
  50. Rever BL, Brickman AS, Sherrard DJ, Coburn JW: Vitamin D responsive, proximal myopathy in chronic renal failure. West Dial Transpl Soc, 1979, p. 46 (abstract)
  51. Schott GD, Wills MR: Muscle weakness in osteomalacia. Lancet 1:626–629, 1976
  52. Mallette LE, Patten EM, Engel WK: Neuromuscular disease in secondary hyperparathyroidism. Ann intern Med 82:474–483, 1975 | PubMed | ISI | ChemPort |
  53. Birge SJ: Vitamin D, muscle and phosphate homeostasis. Min Electrol Metab 1:57–64, 1978
  54. Smith R, Stern G: Myopathy, osteomalacia and hyperparathyroidism. Brain 90:593–602, 1967
  55. Schoenfeld PJ, Martin JA, Barnes B, Teitelbaum SL: Amelioration of myopathy with 25-hydroxyvitamin D3 therapy [25(OH)D3] in patients on chronic hemodialysis. Third Workshop on Vitamin D, Asilomar, California, 1977, p. 160 (abstract)
  56. Rodman JS, Baker T: Changes in the kinetics of muscle contraction in vitamin D-depleted rats. Kidney Int 13:189–193, 1978
  57. Curry OB, Basten JF, Francis MJO, Smith R: Calcium uptake by sarcoplasmic reticulum of muscle from vitamin D-deficient rabbits. Nature 249:83–84, 1974 | Article |
  58. Matthews C, Heimberg KW, Ritz E, Agostini B, Fritzsche J, Hasselbach W: Effect of 1,25-dihydroxy-cholecalciferol in impaired calcium transport by the sarcoplasmic reticulum in experimental uremia. Kidney Int 11:227–235, 1977
  59. Haussler MR, McCain TA: Basic and clinical concepts related to vitamin D metabolism and action. N Engl J Med 297:974–983, 1041–1050, 1977 | PubMed | ChemPort |
  60. Johnson WJ, Goldsmith RS, Beabout JW, Jowsey J, Kelly PJ, Arnaud CD: Prevention and reversal of progressive secondary hyperparathyroidism in patients maintained by hemodialysis. Am J Med 56:827–832, 1974
  61. Canterbury JM, Levey GS, Reiss E: Activation of renal cortical adenylate cyclase by circulating immunoreactive parathyroid fragments. J Clin Invest 52:524–527, 1973
  62. Martin K, Hruska K, Greenwalt A, Klahr S, Slatopolsky E: Selective uptake of intact parathyroid hormone by the liver. Differences between hepatic and renal uptake. J Clin Invest 58:781–788, 1976
  63. Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E: The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest 60:808–814, 1977
  64. Freitag J, Martin KJ, Hruska KA, Anderson C, Conrades M, Ladenson J, Klahr S, Slatopolsky E: Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 298:29–32, 1978 | PubMed | ISI | ChemPort |
  65. Hruska KA, Teitelbaum SL, Kopelman R, Richardson CA, Miller P, Depman J, Martin K, Slatopolsky E: The predictability of the histologic features of uremic bone disease by non-invasive techniques. Metab Bone Dis & Rel Res (Paris) 1:39–44, 1978
  66. Parfitt AM: Clinical and radiographic manifestations of renal osteodystrophy, in Calcium Metabolism in Renal Failure and Nephrolithiasis, edited by David DS, New York, John Wiley & Sons, 1977, p. 150
  67. Meema HE, Oreopoulos DG, Meema S: A roentgenologic study of cortical bone resorption in chronic renal failure. Radiology 126:67–74, 1978
  68. Meema HE, Rabinovich S, Meema S, Lloyd GJ, Oreopoulos DG: Improved radiological diagnosis of azotemic osteodystrophy. Radiology 102:1–10, 1972
  69. Meema HE, Meema S: Microradioscopic quantitation of periosteal resorption in secondary hyperparathyroidism of chronic renal failure. Clin Orthop 130:297–302, 1978
  70. Meema HE, Meema S: Improved roentgenologic diagnosis of osteomalacia by microradioscopy of hand bones. Am J Roentgenol Radium Ther Nucl Med 125:925–935, 1975
  71. Delling G, Schulz A, Schulz W: Morphologische klassifikation der renalen osteopathic. Mels Med Mitt 49:133–140, 1975
  72. Stanbury SW, Lumb GA: Parathyroid function in chronic renal failure: A statistical survey of the plasma biochemistry in azotaemic renal osteodystrophy. Quart J Med 35:1–23, 1966 | PubMed | ChemPort |
  73. Sherrard DJ, Brickman AS, Coburn JW, Singer FR, Maloney N: Skeletal response to treatment with 1,25-dihydroxy-vitamin D in renal failure. Contrib Nephrol 18:92–97, 1979
  74. Coburn JW, Brickman AS, Sherrard DJ, Singer FR, Baylink DJ, Wong EGC, Massry SG, Norman AW: Clinical efficacy of 1,25-dihydroxy-vitamin D3 in renal osteodystrophy, in Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism, edited by Norman, AW, Schaefer, K, Coburn JW, DeLuca HF, Fraser D, Grigoleit HG, von Herrath D, Berlin, W de Gruyter, 1977, p. 657
  75. Brickman AS, Sherrard DJ, Wong EGC, Singer FR, Norman AW, Schaefer K, Coburn JW, DeLuca HF, ration of types by bone histology and response to 1,25(OH)2D3, VIIth International Congress of Nephrology, 1978, p. D-29 (abstract)
  76. Coburn JW, Sherrard DJ, Brickman AS, Wong EGC, Norman AW, Singer FR: A skeletal mineralizing defect in dialysis patients: A syndrome resembling osteomalacia but unrelated to vitamin D. Contrib Nephrol 18:172–183, 1979
  77. Brickman AS, Coburn JW, Sherrard DJ, Wong EGC, Norman AW, Singer FR: Clinical effects of 1,25-dihydroxy-vitamin D3 in uremic patients with overt osteodystrophy. Contrib Nephrol 18:29–41, 1979
  78. Coburn JW, Brickman AS, Sherrard DJ, Singer FR, Wong EGC, Baylink DJ, Norman AW: Use of 1,25(OH)2-vitamin D3 to separate "types" of renal osteodystrophy, in Dialysis, Transplantation, Nephrology, edited by Robinson BHB, Hawkins JB, Vereerstrachfen P, Kent, England, Pitman Medical, 1977, p. 442
  79. Ellis HA, Peart KM: Azotemic renal osteodystrophy, a quantitative study on iliac bone. J Clin Pathol 26:83–101, 1973 | PubMed |
  80. Ellis HA, Pierides AM, Feest TG, Ward MK, Kerr DNS: Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis. Clin Endocrinol 7:31S–38S, 1977
  81. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DNS, Herrington J, Goode GL: Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminum. Lancet 1:841–845, 1978
  82. Kanis JA, Earnshaw M, Henderson RG, Heynen G, Ledingham JGG, Naik RB, Oliver DO, Russell RGG, Smith R, Wilkinson RH, Woods CG: Correlation of clinical, biochemical and skeletal responses to lalpha-hydroxy-vitamin D3 in renal bone disease. Clin Endocrinol 7:45S–50S, 1977
  83. Kanis JA, Ruggell RGG, Naik RB, Earnshaw M, Smith R, Heynen G, Woods CG: Factors influencing the response to 1alpha-hydroxy-vitamin D3 in patients with renal bone disease. Clin Endocrinol 7:51S–57S, 1977
  84. Burnell JM, Teubner E: Effects of decreasing magnesium in patients with chronic renal failure. Proc Clin Dial Transplant Forum 5:191, 1976
  85. Goldstein DA, Malluche HH, Massry SG: Long-term effects of 1,25-(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients. Contrib Nephrol 18:42–54, 1979
  86. Brickman AS, Hartenbower DL, Norman AW, Coburn JW: Actions of 1alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 on mineral metabolism in man. I. Effects on net absorption of phosphorus. Am J Clin Nutr 30:1064–1069, 1977 | PubMed | ISI | ChemPort |
  87. Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry SG, Norman AW: Comparison of effects of 1alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest 57:1540–1547, 1976 | PubMed | ISI | ChemPort |
  88. Kanis JA, Russell RGG: Rate of reversal of hyper-calcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J 1:78–81, 1977 | PubMed | ISI | ChemPort |
  89. Frame B, Parfitt AM: Osteomalacia: Current concepts. Ann Intern Med 89:966–982, 1978
  90. Gipstein RH, Coburn JW, Adams DA, Lee DBN, Parsa KP, Sellers A, Suki WN, Massry SG: Calciphylaxis in man: A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal disease. Arch Intern Med 136:1273–1280, 1976 | Article | PubMed | ISI | ChemPort |
  91. Coburn JW, Llach F: Renal osteodystrophy and maintenance dialysis, in Replacement of Renal Function by Dialysis, edited by Drukker W, Parsons FM, Maher JF, The Hague, Netherlands, Martinus Nijhoff Publishers, 1979, p. 571
  92. Nortman DF, Coburn JW: Altered calcium metabolism and osteodystrophy in end-stage renal failure. Postgrad Med 64:123–130, 1978
  93. Ellis HA, McCarthy JH, Herrington J: Bone aluminium in hemodialysed patients and in rats injected with aluminium chloride; relationship to impaired bone mineralization. J Clin Pathol 32:832–844, 1979
  94. Hodsman AB, Sherrard DJ, Wong EGC, Brickman AS, Lee DBN, Alfrey AC, Singer FR, Coburn JW: Vitamin D-resistant osteomalacia without secondary hyperparathyroidism in dialysis patients. Clin Res 28:560A, 1980 (abstract)
  95. Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I: Deterioration of renal function during treatment of chronic failure with 1,25-dihydroxy-cholecalciferol. Lancet 2:700–703, 1978 | PubMed | ISI | ChemPort |
  96. Ibels LS, Alfrey AC, Haut L, Huffer WF: Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298:122–126, 1978 | PubMed | ISI | ChemPort |
  97. Walser M, Mitch WE, Collier VU: The effect of nutritional therapy on the course of chronic renal failure. Clin Nephrol 11:66–70, 1979
  98. Coburn JW, Wong EGC, Sherrard DJ, Brickman AS, Hodsman AB, Lee DBN, Singer FR, Norman AW: Use of 24,25-dihydroxy vitamin D3 in dialysis osteomalacia: Preliminary results. Clin Res 28:532A, 1980 (abstract)
  99. Gipstein RH, Coburn JW, Adams DA, Lee DBN, Parsa KP, Sellers A, Suki WN, Massry GG: Calciphylaxis in man: A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal disease. Arch Intern Med 136:1273–1280, 1976 | Article | PubMed | ISI | ChemPort |
  100. Gittes RF, Radde IC: Experimental model for hyperparathyroidism: effect of excessive members of transplanted isologous parathyroid glands. J Urol 95:595–603, 1966 | PubMed | ISI | ChemPort |
  101. Mayer GP, Habener JF, Potts JT Jr: Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent non-suppressible component of secretion. J Clin Invest 57:678–683, 1976 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT